Leap Therapeutics Earnings. Is it a Buy?


Leap Therapeutics Earnings. Is it a Buy?: Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2020. 2020 Leap Highlights: Signed agreement with BeiGene, Ltd. for rights to Leap’s anti-DKK1 antibody, DKN-01, in Asia (excluding Japan), Australia and New Zealand Completed a $51.75 million public offering of common stock and pre-funded warrants to […]

Comments

Popular posts from this blog

CWEB - Many household products contain antimicrobial chemicals banned from soaps by the FDA

Thousands of Amazon Employees Receive Layoff Mails, Jeff Bezos’ Surprise Visit at Meeting Sparks Fear Among Washington Post Staff